Difference between revisions of "Pidilizumab (CT-011)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:Drug index" to "Category:Drugs") |
m |
||
| Line 1: | Line 1: | ||
| − | =Mechanism of action= | + | ==Mechanism of action== |
From [http://www.cancer.gov/drugdictionary?CdrID=573227 NCI Drug Dictionary]: A humanized monoclonal antibody directed against human PD-1 (programmed cell death 1; PDCD1), with immunomodulating and antitumor activities. Pidilizumab blocks interaction between the receptor PD-1 with its ligands, PD-1 ligand 1 (PD-1L1) and PD-1 ligand 2 (PD-1L2), resulting in the attenuation of apoptotic processes in lymphocytes, primarily effector/memory T cells, and the augmentation of the anti-tumor activities of NK cells. | From [http://www.cancer.gov/drugdictionary?CdrID=573227 NCI Drug Dictionary]: A humanized monoclonal antibody directed against human PD-1 (programmed cell death 1; PDCD1), with immunomodulating and antitumor activities. Pidilizumab blocks interaction between the receptor PD-1 with its ligands, PD-1 ligand 1 (PD-1L1) and PD-1 ligand 2 (PD-1L2), resulting in the attenuation of apoptotic processes in lymphocytes, primarily effector/memory T cells, and the augmentation of the anti-tumor activities of NK cells. | ||
=Preliminary data= | =Preliminary data= | ||
| − | ==[[Diffuse large B-cell lymphoma]]== | + | ===[[Diffuse large B-cell lymphoma]]=== |
# Armand P, Nagler A, Weller EA, Devine SM, Avigan DE, Chen YB, Kaminski MS, Kent Holland H, Winter JN, Mason JR, Fay JW, Rizzieri DA, Hosing CM, Ball ED, Uberti JP, Lazarus HM, Mapara MY, Gregory SA, Timmerman JM, Andorsky D, Or R, Waller EK, Rotem-Yehudar R, Gordon LI. Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: Results of an international phase II trial. J Clin Oncol. 2013 Nov 20;31(33):4199-206. Epub 2013 Oct 14. [http://jco.ascopubs.org/content/31/33/4199.full link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24127452/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/24127452 PubMed] | # Armand P, Nagler A, Weller EA, Devine SM, Avigan DE, Chen YB, Kaminski MS, Kent Holland H, Winter JN, Mason JR, Fay JW, Rizzieri DA, Hosing CM, Ball ED, Uberti JP, Lazarus HM, Mapara MY, Gregory SA, Timmerman JM, Andorsky D, Or R, Waller EK, Rotem-Yehudar R, Gordon LI. Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: Results of an international phase II trial. J Clin Oncol. 2013 Nov 20;31(33):4199-206. Epub 2013 Oct 14. [http://jco.ascopubs.org/content/31/33/4199.full link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24127452/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/24127452 PubMed] | ||
| − | ==[[Follicular lymphoma]]== | + | ===[[Follicular lymphoma]]=== |
# Westin JR, Chu F, Zhang M, Fayad LE, Kwak LW, Fowler N, Romaguera J, Hagemeister F, Fanale M, Samaniego F, Feng L, Baladandayuthapani V, Wang Z, Ma W, Gao Y, Wallace M, Vence LM, Radvanyi L, Muzzafar T, Rotem-Yehudar R, Davis RE, Neelapu SS. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol. 2014 Jan;15(1):69-77. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70551-5/fulltext?elsca1=ETOC-ONCOLOGY&elsca2=email&elsca3=P24A35F link to original article] Epub 2013 Dec 11. [https://www.ncbi.nlm.nih.gov/pubmed/24332512 PubMed] | # Westin JR, Chu F, Zhang M, Fayad LE, Kwak LW, Fowler N, Romaguera J, Hagemeister F, Fanale M, Samaniego F, Feng L, Baladandayuthapani V, Wang Z, Ma W, Gao Y, Wallace M, Vence LM, Radvanyi L, Muzzafar T, Rotem-Yehudar R, Davis RE, Neelapu SS. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol. 2014 Jan;15(1):69-77. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70551-5/fulltext?elsca1=ETOC-ONCOLOGY&elsca2=email&elsca3=P24A35F link to original article] Epub 2013 Dec 11. [https://www.ncbi.nlm.nih.gov/pubmed/24332512 PubMed] | ||
| + | |||
| + | ==Also known as== | ||
| + | *'''Code name:''' CT-011 | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
Revision as of 18:23, 7 August 2018
Mechanism of action
From NCI Drug Dictionary: A humanized monoclonal antibody directed against human PD-1 (programmed cell death 1; PDCD1), with immunomodulating and antitumor activities. Pidilizumab blocks interaction between the receptor PD-1 with its ligands, PD-1 ligand 1 (PD-1L1) and PD-1 ligand 2 (PD-1L2), resulting in the attenuation of apoptotic processes in lymphocytes, primarily effector/memory T cells, and the augmentation of the anti-tumor activities of NK cells.
Preliminary data
Diffuse large B-cell lymphoma
- Armand P, Nagler A, Weller EA, Devine SM, Avigan DE, Chen YB, Kaminski MS, Kent Holland H, Winter JN, Mason JR, Fay JW, Rizzieri DA, Hosing CM, Ball ED, Uberti JP, Lazarus HM, Mapara MY, Gregory SA, Timmerman JM, Andorsky D, Or R, Waller EK, Rotem-Yehudar R, Gordon LI. Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: Results of an international phase II trial. J Clin Oncol. 2013 Nov 20;31(33):4199-206. Epub 2013 Oct 14. link to original article link to PMC article PubMed
Follicular lymphoma
- Westin JR, Chu F, Zhang M, Fayad LE, Kwak LW, Fowler N, Romaguera J, Hagemeister F, Fanale M, Samaniego F, Feng L, Baladandayuthapani V, Wang Z, Ma W, Gao Y, Wallace M, Vence LM, Radvanyi L, Muzzafar T, Rotem-Yehudar R, Davis RE, Neelapu SS. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol. 2014 Jan;15(1):69-77. link to original article Epub 2013 Dec 11. PubMed
Also known as
- Code name: CT-011